MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
MACROGENICS INC director William K. Heiden reported routine equity compensation activity. On May 19, 2026, he was granted stock options for 22,000 shares of common stock with an exercise price of $4.52 per share, expiring on May 19, 2036. He also received a grant of 3,750 restricted stock units (RSUs) that will vest one year after the grant date or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, bringing his direct common stock holdings to 114,750 shares. These transactions reflect awards and an RSU vesting/exercise, with no open‑market purchases or sales.
MACROGENICS INC director Jay Philip Siegel exercised restricted stock units into common shares. On May 18, 2026, he converted 3,750 restricted stock units into 3,750 shares of common stock at a stated price of $0.00 per share.
The restricted stock units vested on May 18, 2026, one day before the company’s 2026 annual meeting of stockholders held on May 19, 2026. Following this exercise-and-hold transaction, Siegel directly owns 14,750 shares of MacroGenics common stock and no longer holds the vested RSUs as a separate derivative position.
MACROGENICS INC director Margaret Liu reported routine equity compensation activity. She received a stock option grant for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. She was also granted 3,750 restricted stock units, each representing one share of common stock, which will vest one year after the grant date or the day before the next annual meeting, if earlier. Separately, 3,750 previously granted RSUs vested on May 18, 2026 and were exercised into 3,750 shares of common stock, bringing her direct common stock holdings to 14,750 shares.
MACROGENICS INC director Meenu Chhabra reported routine equity compensation activity. On May 19, 2026, she received grants of 3,750 restricted stock units and 22,000 stock options with a conversion or exercise price of $4.5200 per share, both held directly. The options vest in monthly 1/12th increments beginning one month from the grant date, while the RSUs vest one year from grant or the day before the next annual meeting, if earlier.
On May 18, 2026, 3,750 RSUs vested and were exercised into 3,750 shares of common stock, increasing her directly held common stock to 14,750 shares. These transactions reflect compensation-related grants and an RSU vesting and conversion, with no open-market buys or sells reported.
MACROGENICS INC director Edward Hurwitz reported routine equity compensation activity and an option exercise. On May 19, 2026, he received stock options for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036.
He was also granted 3,750 restricted stock units (RSUs), each representing one share of common stock, which will vest one year after the grant date or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, leaving him with 47,824 common shares held directly after the transactions.
MACROGENICS INC director David C. Stump reported routine equity compensation and an option exercise. On May 18, 2026, 3,750 restricted stock units (RSUs) vested and were converted into 3,750 shares of common stock, and he held 14,750 common shares directly afterward. On May 19, 2026, he received a grant of stock options for 22,000 shares at an exercise price of $4.52 per share, expiring on May 19, 2036, plus a new award of 3,750 RSUs. The filing notes that RSUs vest around the company’s annual meetings and that the new options vest monthly in 1/12th increments beginning one month after grant.
MACROGENICS INC director Karen Jean Ferrante reported equity compensation transactions. On May 19, 2026, she received a stock option grant for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. She also received 3,750 restricted stock units (RSUs), each representing one future share of common stock, which vest one year after grant or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, increasing her direct common stock holdings to 14,750 shares.
MacroGenics Inc. director Scott Koenig received new equity awards. He was granted stock options for 22,000 shares of common stock with an exercise price of $4.52 per share, expiring in 2036.
Koenig was also granted 3,750 restricted stock units, each representing one share of common stock. The RSUs vest one year after the grant date, or the day before the next annual meeting if earlier. The options vest in monthly 1/12th increments starting one month after grant.
MacroGenics, Inc. reported results from its 2026 Annual Meeting of Stockholders. A total of 36,744,013 common shares were present or represented by proxy, about 58% of the 63,560,068 shares outstanding and entitled to vote as of March 27, 2026.
Stockholders elected all four Class I director nominees to new three‑year terms and ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026. Stockholders also approved, on an advisory basis, the compensation of the named executive officers.
In addition, stockholders approved an amendment to the 2023 Equity Incentive Plan to increase the number of common shares available for issuance by 1,250,000, expanding the pool available for future equity-based awards.
Armistice Capital, LLCSchedule 13G/A reporting beneficial ownership of 6,012,000 shares of Macrogenics, Inc. common stock, representing 9.46% of the class as of 03/31/2026. The filing explains Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive proceeds and dividends; the Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on 05/15/2026.